keyboard_arrow_up

Regenerative Medicine Partnering Terms and Agreements

Regenerative Medicine Partnering Terms and Agreements is a new market research publication announced by Reportstack. This report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
 
Trends in regenerative medicine 
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
 
The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                                
This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of regenerative medicine dealmaking and business activities. This report provides an introduction to the report, an overview of the trends in regenerative medicine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms,   provides a review of the leading regenerative medicine deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
This report  provides a comprehensive listing of the top 50 big pharma companies that are active in rgenerative medicine partnering with a brief summary followed by a comprehensive listing of deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
This report also provides a comprehensive and detailed review of all regenerative medicine partnering deals including cell therapy, organ regeneration, stem cells and tissue regeneration signed and announced since 2009. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine technologies and products.

Regenerative Medicine  Partnering Terms and Agreements provides the reader with the following key benefits:
 
In-depth understanding of regenerative medicine and stem cells deal trends since 2009
Includes cell therapy, organ regeneration, stem cells and tissue regeneration deals
Access to headline, upfront, milestone and royalty data
Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies, together with real world clause examples
Full listing of regenerative medicine and stem cells deals by company A-Z, deal value, deal type, and therapy focus
Identify leading regenerative medicine and stem cells deals by value since 2009
Identify the most active regenerative medicine and stem cells dealmakers since 2009
Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

To access full report with TOC, please visit Regenerative Medicine Partnering Terms and Agreements.